Vital Chemtech Limited (NSE: VITAL)

By Raveendran R | Updated on:

Source: Vital Chemtech Limited Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026)

Metrics for FY 2025-26 Ended Mar 31, 2026
Profit & Loss (₹ Cr)
Revenue
₹126.44 Cr (▼ 5.6%)
Prev Year: ₹133.90 Cr
Gross Profit
₹29.38 Cr (▲ 4.4%)
Prev Year: ₹28.14 Cr
Operating Profit
₹4.35 Cr (▼ 28.5%)
Prev Year: ₹6.08 Cr
Net Profit
₹1.03 Cr (▼ 74.1%)
Prev Year: ₹3.97 Cr
Ratios & Margins (% / x)
Gross Margin
23.24 % (▲ 222 bps)
Prev Year: 21.02 %
Operating Margin
3.44 % (▼ 110 bps)
Prev Year: 4.54 %
PAT Margin
0.81 % (▼ 215 bps)
Prev Year: 2.96 %
ROCE
3.02 % (▼ 76 bps)
Prev Year: 3.78 %
ROE
1.03 % (▼ 293 bps)
Prev Year: 3.96 %
ROA
0.47 % (▼ 145 bps)
Prev Year: 1.92 %
Asset Turnover
0.58x (▼ 0.07 pts)
Prev Year: 0.65x
Balance Sheet (₹ Cr)
Total Assets
₹218.95 Cr (▲ 5.8%)
Prev Year: ₹207.00 Cr
Current Assets
₹89.94 Cr (▲ 34.2%)
Prev Year: ₹67.03 Cr
Total Liabilities
₹119.00 Cr (▲ 11.5%)
Prev Year: ₹106.70 Cr
Current Liabilities
₹74.83 Cr (▲ 62.2%)
Prev Year: ₹46.14 Cr
Total Debt
₹61.88 Cr (▼ 6.1%)
Prev Year: ₹65.92 Cr
Total Equity
₹99.95 Cr (▼ 0.4%)
Prev Year: ₹100.31 Cr
Working Capital
₹15.11 Cr (▼ 27.7%)
Prev Year: ₹20.89 Cr
Ratios & Margins (% / x)
Current Ratio
1.20x (▼ 0.25 pts)
Prev Year: 1.45x
Debt to Equity
0.62x (▼ 0.04 pts)
Prev Year: 0.66x
Debt to Assets
0.28x (▼ 0.04 pts)
Prev Year: 0.32x
Equity Multiplier
2.19x (▲ 0.13 pts)
Prev Year: 2.06x
Cash Flow (₹ Cr)
Operating Cash Flow
₹4.92 Cr (▼ 16.9%)
Prev Year: ₹5.92 Cr
CapEx
₹23.52 Cr (▼ 48.6%)
Prev Year: ₹45.78 Cr
Free Cash Flow
-₹18.60 Cr (▲ 53.3%)
Prev Year: -₹39.86 Cr
Ratios & Margins (% / x)
FCF Margin
-14.71 % (▲ 1506 bps)
Prev Year: -29.77 %
Cash ROCE
3.41 % (▼ 27 bps)
Prev Year: 3.68 %
Cash ROE
4.92 % (▼ 98 bps)
Prev Year: 5.90 %
CF to Debt
0.08x (▼ 0.01 pts)
Prev Year: 0.09x

📋 Quick Facts: Company Snapshot

Attribute Disclosed Detail
Official Company Name Vital Chemtech Limited
Corporate Identity Number (CIN) L24299GJ2021PLC127538
ISIN INE0L4K01016
Stock Exchange Listing National Stock Exchange of India Limited (NSE Symbol: VITAL)
Date of Incorporation / Corporate Evolution November 11, 2013 (as Rudra Chemtech Private Limited); converted to LLP on February 12, 2015; name changed to Vital Chemtech LLP on February 20, 2015; converted to Public Limited Company on November 25, 2021
Founders / Key Founding Figures Mr. Vipul Jatashanker Bhatt (originating commercial operations under Vital Chemicals in 1993)
Registered Office & Corporate Headquarters B-406, Mondeal Heights, Opp. Karnavati Club, S. G. Highway, Ahmedabad – 380015, Gujarat, India
Telephone & Investor Relations Contact Tel: +91 79 4600 5840; Email: compliance@vitalgroup.co.in / info@vitalgroup.co.in
Chairman & Managing Director Mr. Vipul Jatashanker Bhatt (DIN: 06716658)
Key Managerial Personnel (KMP) Mr. Jay Vipul Bhatt (Whole-Time Director); Mr. Jitendra Raval (CFO w.e.f. August 15, 2026; Mr. Vipul Bhatt served as CFO Oct 7, 2025 to Aug 14, 2026; Ms. Ketki Ajay Oza up to July 5, 2025); Ms. Atula Patel (Company Secretary & Compliance Officer)
Promoter & Operating Group Vital Group (Promoters: Mr. Vipul Bhatt, Mrs. Sangeeta Bhatt, Mr. Jay Bhatt)
Industry Classification Specialty Chemicals / Phosphorus Derivative Chemistry
Total Permanent Employees 59 permanent employees on rolls (as of March 31, 2026)
Manufacturing Complex & Installed Capacity Plot No. D-3/151 & 158, G.I.D.C. Dahej Industrial Estate, PCPIR Region, Gujarat – 392130 (32,000 MTPA capacity across 4 dedicated manufacturing blocks)
Statutory Auditor M/s. Abhishek Kumar & Associates, Chartered Accountants (Firm Registration No. 130052W)
Secretarial Auditor M/s. SCS and Co. LLP, Practicing Company Secretaries (Firm Registration No. L2020GJ008700 / Peer Review No. 5333/2023)
Cost Auditor M/s. R J & Associates, Cost Accountants (Firm Registration No. 004690)
Registrar and Share Transfer Agent (RTA) Skyline Financial Services Private Limited, D-153A, 1st Floor, Okhla Industrial Area, Phase-1, New Delhi – 110020

🏢 The Corporate Identity: Vital Chemtech Overview, Promoters & History

The Big Picture: Business Model & Core Value Proposition

Vital Chemtech Limited operates as an integrated manufacturer and exporter in the phosphorus derivative chemical domain, executing high-hazard chemistries from its integrated manufacturing complex in the Petroleum, Chemicals and Petrochemicals Investment Region (PCPIR) at Dahej, Gujarat. The company manufactures specialized downstream inorganic phosphorus chemicals that serve as critical building blocks, chlorinating agents, dehydrating precursors, and catalyst linkers across life sciences, agrochemicals, plastics, performance pigments, and energy storage technologies.

The enterprise functions primarily on a purchase-order-driven B2B business model, selling specialized reactive intermediates directly to end-use industrial manufacturers. By maintaining dedicated reaction scales between 1,000 liters and 20,000 liters, automated via Programmable Logic Controller (PLC) and Supervisory Control and Data Acquisition (SCADA) systems, Vital Chemtech delivers process safety, batch uniformity, and regulatory compliance. The production complex operates under strict Zero Liquid Discharge (ZLD) protocols to maintain environmental and occupational safety standards certified under ISO 9001:2015, ISO 14001:2015, and ISO 45001:2018.

The Founders, Promoters & Their Legacy

The operational foundation of the Vital Group traces back to 1993, when Mr. Vipul Jatashanker Bhatt commenced business by establishing Vital Chemicals, focusing on the trading and distribution of phosphorus derivatives, organophosphates, and specialty polymers. Holding a Diploma in Chemical Engineering from Government Engineering College, Bharuch, Mr. Bhatt brings over 31 years of domain expertise in chemical manufacturing, hazardous material handling, and process synthesis.

The executive leadership is augmented by the second generation of the promoter family, led by Mr. Jay Vipul Bhatt, Whole-Time Director. Mr. Jay Bhatt holds a Bachelor of Engineering in Chemical Engineering from Gujarat Technological University and an MSc in Management from Queen Mary University of London. He oversees business development, operations, and technical scaling across the group’s manufacturing sites. Mrs. Sangeeta Vipul Bhatt, who transitioned from Whole-Time Director to Non-Executive Director on June 14, 2025, forms an integral part of the promoter group, which collectively held a controlling 73.43% equity stake in the company as of March 31, 2026.

The Journey: Corporate History & Key Milestones

Over three decades, the business progressed from raw chemical trading into fully integrated, multi-ton specialty manufacturing:

  • 1993: Commercial inception through Vital Chemicals, trading in phosphorus derivatives, organophosphates, and polymers.
  • 2013: Incorporation of Rudra Chemtech Private Limited on November 11, 2013, to construct greenfield manufacturing infrastructure.
  • 2015: Conversion of the private corporate entity into a Limited Liability Partnership (LLP) under the name Rudra Chemtech LLP on February 12, 2015, subsequently renamed Vital Chemtech LLP on February 20, 2015; commercial commissioning of the integrated manufacturing plant at Dahej, Gujarat.
  • 2018: Commercialization of downstream product lines, commencing commercial production of Phosphorus Pentachloride (PCl5) and Phosphorus Pentoxide (P2O5).
  • 2019: Scale-up of catalyst lines through commercial production of Poly Phosphoric Acid (PPA).
  • 2020: Enterprise-wide digital transformation, undertaking complete SAP ERP implementation and transitioning critical plant operations to automated PLC and SCADA controls.
  • 2021: Conversion of the partnership firm into a public limited entity, Vital Chemtech Limited, on November 25, 2021.
  • 2022: Successful completion of the initial public offering (IPO) on the SME Platform (NSE Emerge) of the National Stock Exchange of India; crossing the ₹100 Crore annual topline milestone; completion of manufacturing capacity augmentation from 13,200 MTPA to 28,800 MTPA; incorporation of subsidiary Vital Synthesis Private Limited.
  • 2023: Acquisition of a 70.00% controlling stake in Vital Alkoxides Private Limited on March 31, 2023, diversifying into alkoxide derivative chemistries.
  • 2024: Commencement of commercial manufacturing operations at Vital Alkoxides Private Limited.
  • 2025: Scaling operational capacity to 32,000 MTPA across 4 blocks; Vital Alkoxides achieved positive EBITDA in its first full operational year; construction reached advanced stages at Vital Synthesis Limited.
  • 2026: Migration of Vital Chemtech Limited’s equity shares from the NSE Emerge SME platform to the Main Board of the National Stock Exchange of India Limited (NSE) with effect from March 11, 2026; commercial production successfully commenced at subsidiary Vital Synthesis Limited.

The Corporate Umbrella & Group Structure

Vital Chemtech Limited operates as the flagship corporate parent of the Vital Group, anchoring an ecosystem of chemical manufacturing assets situated within the Dahej PCPIR industrial cluster. The parent company directly controls two operating subsidiaries:

  • Vital Synthesis Limited: A 99.00% owned subsidiary incorporated on April 26, 2022, established to manufacture organic and inorganic industrial chemicals, advanced chemical intermediates, active pharmaceutical inputs, and specialty compounds. The subsidiary completed construction and commenced commercial operations towards the end of FY 2025-26.
  • Vital Alkoxides Private Limited: A 70.00% owned subsidiary acquired on March 31, 2023, specializing in the synthesis of alkoxide derivatives and fine performance intermediates. The entity generated ₹23.01 Crores in revenue during FY 2025-26.
  • Associate & Related Concerns: Include Vital Chemicals (sole proprietorship of Managing Director Vipul Bhatt), Vital Wellness Limited, and Valentia Synthesis Private Limited.

⚙️ The Business Engine: Segments, Brands, Products & Operations

The Core Divisions & Segment Revenue Breakdown

Vital Chemtech Limited operates in a single primary business segment: the manufacturing and trading of chemical products. In accordance with Ind AS 108 Operating Segments, the company’s chief operating decision-maker reviews enterprise performance at the consolidated chemical operations level, as all production lines share similar economic characteristics, production technologies, and regulatory distribution channels.

Business Activity FY 2025-26 Revenue (₹ in Crores) % Share of Total Revenue FY 2024-25 Revenue (₹ in Crores) % Share of Total Revenue Latest YoY (%)
Manufacturing of Specialty Chemicals & Derivatives 126.44 100.00% 133.90 100.00% -5.57%
Trading of Chemical Raw Materials 0.00 0.00% 0.00 0.00% N/M
Total Revenue from Operations 126.44 100.00% 133.90 100.00% -5.57%

On a standalone basis, Vital Chemtech Limited generated ₹1.05 Crores in revenue from operations for FY 2025-26, compared to ₹120.23 Crores in FY 2024-25. The consolidation of subsidiary operations—specifically Vital Alkoxides Private Limited (₹23.01 Crores) and initial output from Vital Synthesis Limited (₹3.06 Crores), net of intercompany eliminations—lifted consolidated operational turnover to ₹126.44 Crores.

The Product & Service Catalog (with Operational KPIs & Order Book)

The manufacturing complex in Dahej produces six primary high-volume phosphorus derivatives, providing critical chemical functionality across pharmaceutical synthesis, crop protection, and polymer engineering:

  • Phosphorus Trichloride (PCl3): A fuming liquid chlorinating intermediate used extensively across crop care synthesis (organophosphate insecticides like diazinon), flame retardants, and PVC plasticizers. It serves as the base feedstock to synthesize downstream phosphorus oxychloride and phosphorus pentachloride.
  • Phosphorus Oxychloride (POCl3): A high-utility chlorinating agent and organic linker vital for life science active pharmaceutical ingredients (APIs)—including pantoprazole and oncology therapeutics—and semiconductor wafer diffusion processes.
  • Phosphorus Pentachloride (PCl5): A powerful chlorinating agent and reactive intermediate utilized in the synthesis of semi-synthetic cephalosporin and penicillin antibiotics, water treatment chemicals, and emerging electrolytes for lithium-ion battery energy storage.
  • Phosphorus Pentoxide (P2O5): A fine white amorphous powder exhibiting high dehydration characteristics, used as a laboratory and industrial dehydrating agent, an intermediate for phosphate esters and quinacridone pigments, and a catalyst in specialty organic transformations.
  • Poly Phosphoric Acid (PPA): A viscous, hygroscopic polymeric mineral acid functioning as a catalyst in acylation, alkylation, and cyclization reactions for dyes, safety equipment resins, and asphalt binder modification to prevent pavement rutting and cracking.
  • Phosphorus Pentasulfide (P2S5): An inorganic yellow solid compound utilized as a primary thionating agent in organic synthesis, a precursor for agricultural insecticides (malathion), and an essential raw material for Zinc Dialkyldithiophosphate (ZDDP), a wear-preventing antioxidant lubricant additive in automotive engine oils.

Operational KPIs & Sourcing Split:

  • Aggregate Plant Capacity: 32,000 Metric Tonnes Per Annum (MTPA) installed capacity across 4 dedicated manufacturing blocks.
  • Reaction Vessels Scale: Vessel reaction capacities engineered from 1,000 liters up to 20,000 liters.
  • Customer Concentration Profile: Operating under a disciplined counterparty risk model, no individual customer accounts for more than 10.00% of gross revenues, and the top five customers collectively contribute less than 25.00% of total revenue.
  • Import vs. Indigenous Sourcing: The company relies on international markets for critical elemental yellow phosphorus and raw chemical inputs, recording a CIF value of imports of ₹78.20 Crores during FY 2025-26, compared to ₹1.04 Crores in total consolidated raw material consumption.

The Names You Know: Key Brands & Flagship Portfolio

While operating within the specialized B2B industrial intermediate arena, Vital Chemtech markets its specialized chemical derivative lines under technical product grades tailored to exacting end-user purity specifications:

Brand / Product Name Category / Business Segment Target Market & Key Positioning
Vital PCl3 (Phosphorus Trichloride) Basic Phosphorus Intermediate Agrochemical technical grade synthesis, flame retardant additives, and organophosphates
Vital POCl3 (Phosphorus Oxychloride) Specialty Chlorinating Agent Pharmaceutical APIs (Oncology, Pantoprazole), semiconductor liquid dopant sources
Vital PCl5 (Phosphorus Pentachloride) Reactive Chlorinating Intermediate Antibiotic core synthesis (penicillins/cephalosporins), lithium-ion battery electrolyte precursors
Vital P2O5 (Phosphorus Pentoxide) Dehydrating Agent & Precursor Phosphate esters, high-performance pigments (Quinacridone), and textile processing auxiliaries
Vital PPA (Poly Phosphoric Acid) High-Strength Acid Catalyst Specialty polymers, fire-resistant high-performance fibers, dyes, and modified asphalt binders
Vital P2S5 (Phosphorus Pentasulfide) Thionating & Sulfurizing Agent Automotive engine oil ZDDP anti-wear additives, flotation reagents, and crop care insecticides

Mapping the Domestic & Global Reach (India vs. Exports)

Vital Chemtech’s operational footprint is anchored in the Indian domestic industrial market, serving multinational and domestic crop protection, pharmaceutical, and dyestuff conglomerates. Direct exports constitute an incremental component of top-line revenues:

Geographic Market FY 2025-26 Revenue (₹ in Crores) % Share of Total Revenue FY 2024-25 Revenue (₹ in Crores) % Share of Total Revenue Latest YoY (%)
Domestic Market (India) 125.81 99.50% 133.90 100.00% -6.04%
International Market (Exports) 0.63 0.50% 0.00 0.00% N/M
Total Revenue from Operations 126.44 100.00% 133.90 100.00% -5.57%

Export revenue reached an FOB value of ₹0.63 Crores ($75,111 in direct foreign currency receipts) during FY 2025-26, reflecting the company’s nascent global market penetration across specialty chemical corridors.

The Brick & Mortar Footprint: Manufacturing Plants, R&D & Offices

The company executes all manufacturing from an integrated complex designed with specialized process engineering:

  • Dahej Manufacturing Complex: Situated at Plot No. D-3/151 & 158, G.I.D.C. Dahej Industrial Estate, PCPIR region, Gujarat – 392130. The installation houses four dedicated manufacturing blocks featuring an aggregate 32,000 MTPA capacity, equipped with specialized chlorine handling SKID systems, multi-stage PLC/SCADA-operated scrubbing towers, dedicated firewater networks, and Zero Liquid Discharge (ZLD) effluent treatment facilities.
  • Subsidiary Manufacturing Complexes: Dedicated operational facilities for Vital Alkoxides Private Limited and Vital Synthesis Limited situated within the Dahej chemical belt.
  • Registered Office: B-406, Mondeal Heights, Opp. Karnavati Club, S. G. Highway, Ahmedabad – 380015, Gujarat.

📊 The Financial Health: The Numbers Simplified

During the fiscal year ended March 31, 2026, Vital Chemtech Limited transitioned its corporate accounting framework to Indian Accounting Standards (Ind AS) following its migration to the Main Board of the National Stock Exchange of India. Consolidated financial statements consolidate the operational accounts of Vital Alkoxides Private Limited (70.00% stake) and Vital Synthesis Limited (99.00% stake).

Earnings, Expenses, & Take-Home Profits (Consolidated Profit & Loss)

Consolidated revenue from operations contracted by 5.57% to ₹126.44 Crores in FY 2025-26, down from ₹133.90 Crores in FY 2024-25, impacted by global chemical pricing volatility and demand rationalization across pharmaceutical and agrochemical intermediate sectors. Consolidated Profit Before Tax stood at ₹2.09 Crores compared to ₹5.99 Crores in the preceding year, while Consolidated Net Profit for the year was ₹1.03 Crores (with ₹0.76 Crores attributable to the owners of the parent and ₹0.28 Crores attributable to non-controlling interests) versus ₹3.97 Crores in FY 2024-25.

Statement of Profit and Loss FY 2025-26 (₹ in Crores) FY 2024-25 (₹ in Crores) Latest YoY (%)
Revenue from Operations 126.44 133.90 -5.57%
Other Income 0.86 2.08 -58.65%
Net Gain on Re-measurement of Financial Assets 0.30 0.43 -30.23%
Total Income 127.61 136.41 -6.45%
Cost of Material Consumed 103.82 107.39 -3.32%
Change in Inventory of Finished Goods, Work in Progress & Stock in Trade (6.76) (1.63) +314.72%
Employee Benefits Expense 7.10 5.61 +26.56%
Finance Costs 3.12 2.17 +43.78%
Depreciation and Amortization Expense 5.99 4.97 +20.52%
Other Expenses 12.24 11.90 +2.86%
Total Expenses 125.52 130.42 -3.76%
Profit Before Exceptional Items and Tax 2.09 5.99 -65.11%
Profit Before Tax 2.09 5.99 -65.11%
Current Tax 0.87 1.80 -51.67%
Deferred Tax 0.19 0.22 -13.64%
Profit for the Year 1.03 3.97 -74.06%
Other Comprehensive Income (Remeasurement of Defined Benefit Plans, Net of Tax) 0.02 0.03 -33.33%
Total Comprehensive Income for the Year 1.04 4.00 -74.00%
Owners of the Parent Share in Total Comprehensive Income 0.76 4.00 -81.00%
Non-Controlling Interests Share in Total Comprehensive Income 0.28 0.00 N/M
Basic Earnings Per Equity Share (₹) 0.44 1.67 -73.65%
Diluted Earnings Per Equity Share (₹) 0.43 1.66 -74.10%

The divergence between standalone net profit (₹8.95 Crores) and consolidated net profit (₹1.03 Crores) was driven by pre-commissioning operational expenses and trial run expenditures incurred at subsidiary Vital Synthesis Limited, which posted a net loss of ₹1.39 Crores for the year, alongside consolidation accounting eliminations.

Assets, Borrowings, & Net Worth (Consolidated Balance Sheet)

The consolidated balance sheet expanded to ₹218.95 Crores as of March 31, 2026, compared to ₹207.00 Crores at the close of FY 2024-25. The capital deployment into Capital Work-in-Progress (CWIP) rose to ₹42.83 Crores, reflecting the infrastructure build-out at Vital Synthesis Limited and expansion works across Dahej.

Consolidated Balance Sheet As at March 31, 2026 (₹ in Crores) As at March 31, 2025 (₹ in Crores) Latest YoY (%)
ASSETS
Non-Current Assets
Property, Plant & Equipment 58.25 68.14 -14.51%
Capital Work in Progress (CWIP) 42.83 15.41 +177.94%
Financial Assets: Non-Current Investments 12.97 12.66 +2.45%
Financial Assets: Long-Term Loans & Advances 0.00 17.83 -100.00%
Financial Assets: Long-Term Trade Receivables 5.45 7.50 -27.33%
Financial Assets: Other Non-Current Financial Assets 6.93 16.60 -58.25%
Other Non-Current Assets 2.57 1.82 +41.21%
Total Non-Current Assets 129.01 139.98 -7.84%
Current Assets
Inventories 31.78 13.63 +133.16%
Trade Receivables 39.95 38.91 +2.67%
Cash & Cash Equivalents 0.89 0.82 +8.54%
Other Current Assets 17.31 13.66 +26.72%
Total Current Assets 89.94 67.03 +34.18%
TOTAL ASSETS 218.95 207.00 +5.77%
EQUITY AND LIABILITIES
Equity
Equity Share Capital 23.95 23.95 0.00%
Other Equity 75.40 75.75 -0.46%
Non-Controlling Interest 0.60 0.60 0.00%
Total Equity / Net Worth 99.95 100.31 -0.36%
Non-Current Liabilities
Non-Current Borrowings 43.04 58.14 -25.97%
Non-Current Trade Payables (MSME) 0.29 1.83 -84.15%
Non-Current Provisions 0.19 0.11 +72.73%
Deferred Tax Liabilities (Net) 0.65 0.46 +41.30%
Total Non-Current Liabilities 44.16 60.55 -27.07%
Current Liabilities
Current Borrowings 18.84 7.78 +142.16%
Current Trade Payables: Micro and Small Enterprises 1.57 5.29 -70.32%
Current Trade Payables: Other than Micro and Small 47.72 27.90 +71.04%
Other Financial Current Liabilities 2.80 2.51 +11.55%
Other Current Liabilities 2.86 1.22 +134.43%
Current Provisions 0.18 0.00 N/M
Current Tax Liabilities (Net) 0.87 1.44 -39.58%
Total Current Liabilities 74.83 46.14 +62.18%
Total Liabilities (Non-Current + Current) 119.00 106.70 +11.53%
TOTAL EQUITY AND LIABILITIES 218.95 207.00 +5.77%

Statutory Ratio Variances & Working Capital Dynamics:

  • Consolidated Current Ratio: Moved from 1.45x in FY 2024-25 to 1.20x in FY 2025-26 as working capital borrowings and trade payables expanded to support raw material inventory build-up.
  • Consolidated Debt-to-Equity Ratio: Stood at 0.62x as of March 31, 2026, improving from 0.66x in the previous fiscal year, as aggregate long-term debt was amortized. On a standalone basis, the Debt-to-Equity ratio stood at 0.10x.
  • Inventory Turnover Ratio: Decreased to 4.27x consolidated (5.09x standalone) from 8.21x in FY 2024-25, caused by raw material procurement cycles and stock build-up at ₹31.78 Crores ahead of commercial scale-up at Vital Synthesis Limited.
  • Working Capital Cycle: Trade receivable days averaged 133 days (receivable turnover of 2.75x) while trade payable days averaged 133 days (payable turnover of 2.75x), establishing working capital equilibrium between supplier credit terms and customer collection milestones.

Cash Flow: Tracking the Money Movement

The consolidated cash flow reveals steady operating cash generation deployed into physical plant infrastructure, funded through internal accruals and capital restructuring.

Consolidated Statement of Cash Flows FY 2025-26 (₹ in Crores) FY 2024-25 (₹ in Crores) Latest YoY (%)
Operating Profit Before Working Capital Changes 10.07 11.24 -10.41%
Working Capital Adjustments (4.16) (3.29) +26.44%
Cash Generated from Operations 5.91 7.95 -25.66%
Direct Taxes Paid (Net of Refunds) (0.99) (2.03) -51.23%
Net Cash from Operating Activities 4.92 5.92 -16.89%
Purchase of Property, Plant & Equipment (CapEx) 23.52 45.78 -48.62%
Decrease / (Increase) in Long-Term Loans & Advances 17.83 (17.83) N/M
(Increase) / Decrease in Investments (Net) (0.60) 22.47 N/M
Interest Received 0.86 2.08 -58.65%
Net Cash Used in Investing Activities (5.43) (39.07) -86.10%
Proceeds from Other Non-Current Financial Assets 3.02% 3.78% –
Proceeds from Short-Term Borrowings (Net) 3.02% 3.78% –
Proceeds from / (Repayment of) Long-Term Borrowings (Net) 3.02% 3.78% –
Decrease / (Increase) in Reserves / Other Equity (1.92) 11.56 N/M
Finance Costs Paid (3.12) (2.17) +43.78%
Changes in Non-Controlling Interests 0.00 0.56 -100.00%
Net Cash from / (Used in) Financing Activities 0.58 33.49 -98.27%
Net Increase / (Decrease) in Cash & Cash Equivalents 0.07 0.34 -79.41%
Cash & Cash Equivalents at Beginning of the Year 0.82 0.48 +70.83%
Cash & Cash Equivalents at End of the Year 0.89 0.82 +8.54%

Funding the Future: CapEx, CWIP, R&D & Foreign Exchange

The company continued its multi-year capital deployment strategy to enhance capacity and backward integration across its subsidiaries:

  • Capital Expenditure & CWIP: Consolidated cash CapEx on property, plant, and equipment reached ₹23.52 Crores during FY 2025-26, following ₹45.78 Crores deployed in FY 2024-25. Capital Work-in-Progress stood at ₹42.83 Crores as of March 31, 2026, comprising ongoing plant building and machinery installations at Vital Synthesis Limited.
  • Research & Development: The company focuses on in-house process optimization, yield recovery, and catalytic synthesis. No separate standalone R&D capital expenditures were capitalized under Section 134(3)(m).
  • Foreign Exchange Dynamics: Vital Chemtech recorded foreign exchange earnings via export sales of ₹0.63 Crores ($75,111 in direct foreign receipts). Conversely, foreign exchange outgoings amounted to ₹78.20 Crores for CIF value of chemical raw material imports and ₹0.87 Crores in foreign currency expense disbursements.

👥 Power & Control: Corporate Governance, Leadership & Ownership

The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)

Vital Chemtech maintains a 6-member Board of Directors comprising two Executive Directors, one Non-Executive Non-Independent Director, and three Non-Executive Independent Directors, ensuring governance compliance under Regulation 17 of SEBI LODR Regulations.

Name of Director / KMP Designation / Role DIN Category
Mr. Vipul Jatashanker Bhatt Chairman & Managing Director 06716658 Executive / Promoter
Mr. Jay Vipul Bhatt Whole-Time Director 09363173 Executive / Promoter
Mrs. Sangeeta Vipul Bhatt Non-Executive Director 06716704 Non-Executive / Promoter
Mr. Deepakkumar Kushalchandra Chaubisa Independent Director 09629889 Non-Executive / Independent
Mr. Ajay Kumar Agrawal Independent Director 05274908 Non-Executive / Independent
Mr. Vivek Dinesh Nathwani Independent Director 09791683 Non-Executive / Independent
Mr. Jitendra Raval Chief Financial Officer (w.e.f. Aug 15, 2026) Not Applicable Key Managerial Personnel
Ms. Atula Patel Company Secretary & Compliance Officer Not Applicable Key Managerial Personnel

Board Changes & Governance Details:

  • Mr. Suneel Mundra resigned as an Independent Director with effect from May 30, 2025, due to personal circumstances. Mr. Vivek Dinesh Nathwani was appointed to fill the casual vacancy on May 30, 2025, and subsequently regularized for a 5-year term by shareholders at the 4th AGM on September 27, 2025.
  • Mrs. Sangeeta Vipul Bhatt transitioned from Whole-Time Director to Non-Executive Director on June 14, 2025.
  • Ms. Ketki Ajay Oza resigned as Chief Financial Officer on July 5, 2025. Managing Director Mr. Vipul Bhatt assumed the CFO role on October 7, 2025, stepping down on August 14, 2026, upon the appointment of Mr. Jitendra Raval as CFO on August 15, 2026.
  • The Board of Directors convened 8 times during FY 2025-26, with 100% attendance across all continuing directors.

Who Owns the Stock? Shareholding Pattern

The company’s paid-up equity share capital is ₹23.95 Crores, consisting of 2,39,51,100 fully paid equity shares of face value ₹10 each. The shareholding structure as of March 31, 2026, was distributed as follows:

Shareholder Category Number of Shares Held % of Total Equity Capital
Promoter & Promoter Group 1,75,87,500 73.43%
Mr. Vipul Jatashanker Bhatt 1,31,98,500 55.11%
Mrs. Sangeeta Vipul Bhatt 43,87,500 18.32%
Mr. Jay Vipul Bhatt 300 0.00%
Vipul Bhatt HUF 300 0.00%
Other Promoter Group Relatives (3 individuals) 900 0.00%
Public Institutional Investors 4,47,600 1.87%
Foreign Portfolio Investors (FPIs) 3,87,600 1.62%
Non-Banking Financial Companies (NBFCs) 60,000 0.25%
Public Non-Institutional Investors 59,16,000 24.70%
Resident Individuals 50,48,584 21.08%
Resident Indian Hindu Undivided Families (HUFs) 4,89,319 2.04%
Bodies Corporate 3,00,097 1.25%
Non-Resident Indians (NRIs) 56,400 0.24%
Clearing Members, Firms & Trusts 21,600 0.09%
Total Equity Share Capital 2,39,51,100 100.00%

100.00% of the company’s equity capital is held in dematerialized form (90.97% with CDSL and 9.03% with NSDL across 2,023 registered shareholders). None of the promoter shareholdings were pledged as of March 31, 2026.

🗺️ The Corporate Family Tree: Group Structure & Strategic Investments

Subsidiaries, Associates, & Joint Ventures (Form AOC-1)

The operational and financial metrics of Vital Chemtech’s direct subsidiaries for the year ended March 31, 2026, pursuant to Section 129(3) of the Companies Act, 2013, are outlined below:

Entity Name Relationship Country % Equity Stake Turnover (₹ in Crores) Profit / (Loss) After Tax (₹ in Crores)
Vital Synthesis Limited Direct Subsidiary India 99.00% 3.06 (1.39)
Vital Alkoxides Private Limited Direct Subsidiary India 70.00% 23.01 0.95

Vital Alkoxides Private Limited delivered a net profit of ₹0.95 Crores on turnover of ₹23.01 Crores, operating profitably in its first full operational cycle. Vital Synthesis Limited recorded initial revenues of ₹3.06 Crores and a net loss of ₹1.39 Crores due to fixed overheads during plant commissioning.

Strategic Investments, Credit Facilities & Contingent Liabilities

The company maintains non-current quoted investments in bonds valued at ₹5.96 Crores as of March 31, 2026, compared to ₹5.66 Crores in FY 2024-25, alongside fixed deposits with banks of ₹6.93 Crores.

Credit Facilities & Security Profiles:

  • Working capital facilities (cash credit, overdraft, and letters of credit) with ICICI Bank Limited and HDFC Bank Limited are secured by hypothecation of current assets, inventories, and book debts, collaterally supported by liquid securities and personal guarantees of executive directors.
  • Term loan facilities from banks stood at ₹4.02 Crores (gross), secured against specific plant, machinery, and vehicles. Unsecured loans from related parties stood at ₹9.64 Crores.
  • Contingent Liabilities: No material pending legal litigation exposures or capital demands exist against the enterprise, except for outstanding Letters of Credit (LCs) amounting to ₹2.31 Crores as of March 31, 2026.

🎯 The Strategic Outlook: Competitive Moats, Risks & Future Growth Plans

Competitive Advantages & Economic Moats

  • High Regulatory & Technical Entry Barriers: Phosphorus derivative synthesis involves high-hazard reactive chemistry utilizing elemental yellow phosphorus, dry chlorine gas, and anhydrous media. Developing process automation, environmental safety scrubbing, and regulatory handling approvals requires multi-year lead times and complex engineering expertise.
  • Infrastructure in PCPIR Dahej Hub: Operating in the Dahej PCPIR cluster ensures uninterrupted power, deep-water port access, common effluent handling infrastructure, and proximity to Gujarat’s dyestuff, agrochemical, and pharmaceutical corridors.
  • Automated Zero Liquid Discharge (ZLD) Infrastructure: The manufacturing complex operates with closed-loop multi-stage PLC/SCADA scrubbers, emergency chlorine neutralization SKIDs, and ZLD systems, satisfying stringent Gujarat Pollution Control Board norms.
  • Diversified Product & Customer Footprint: Serving across crop protection, pharmaceuticals, pigments, performance plastics, and lubricant additives protects the business from single-sector downturns, with no individual customer exceeding 10.00% of revenue.

What Could Go Wrong? Key Challenges & Business Risks

  • Raw Material Import Dependence: The business relies on imported yellow phosphorus, subjecting gross margins to international commodity pricing swings, sea-freight rate spikes, and geopolitical tensions across supply routes. CIF imports reached ₹78.20 Crores during FY 2025-26.
  • Hazardous Chemistry & Occupational Risks: Phosphorus compounds (PCl3, POCl3, PCl5, P2S5) are fuming, toxic, corrosive, and water-reactive. While safety systems are automated, containment or handling disruptions pose operational and regulatory risks (exemplified by a brief plant disruption at the P2S5 unit on May 16, 2025).
  • Consolidated Profitability Drag from Ramp-Up: While standalone operations delivered ₹8.95 Crores in net profit, consolidated profit dropped to ₹1.03 Crores due to early-stage fixed costs and trial overheads at Vital Synthesis Limited. Delay in subsidiary utilization could compress consolidated returns.

The Next Chapter: Growth, Order Pipeline & CapEx Initiatives

Vital Chemtech’s forward strategy centers on commissioning downstream capacity, diversifying chemistry streams, and expanding its presence in advanced materials:

  • Commercial Scaling of Vital Synthesis: With commercial production commenced at the end of FY 2025-26, the company expects Vital Synthesis Limited to scale production of advanced fine chemicals, pharmaceutical intermediates, and custom synthesis molecules, leveraging the ₹42.83 Crores invested in plant facilities.
  • Main Board Visibility & Institutional Access: Migrating to the Main Board of the National Stock Exchange of India (effective March 11, 2026) enhances institutional investor participation, liquidity, and governance oversight.
  • Advanced Technology Applications: Developing specialized high-purity phosphorus precursors (PCl5) for use in lithium-ion battery electrolytes and semiconductor wafer fabrication processes, expanding beyond traditional agrochemical and dyestuff markets.

The Verdict: Strategic Outlook & Conclusion

Vital Chemtech Limited has evolved from a regional chemical trading house into an automated, multi-site manufacturer of hazardous phosphorus and alkoxide derivatives. While cyclical headwinds in the global chemical sector and subsidiary commissioning overheads compressed consolidated net profit to ₹1.03 Crores in FY 2025-26, standalone margins improved, with standalone net profit expanding 29.32% to ₹8.95 Crores. With an integrated asset base of ₹218.95 Crores, net worth of ₹99.95 Crores, a conservative standalone debt profile (0.10x D/E), and commercial operations underway at Vital Synthesis Limited, the enterprise is structured to benefit from supply chain realignments across specialty chemical corridors.

Frequently Asked Questions (FAQs) About Vital Chemtech

Q1: What is the core business and product portfolio of Vital Chemtech Limited?

Vital Chemtech Limited is an Indian specialty chemical manufacturer focused on phosphorus derivative chemistry. Operating from Dahej, Gujarat, the company manufactures six primary products: Phosphorus Trichloride (PCl3), Phosphorus Oxychloride (POCl3), Phosphorus Pentachloride (PCl5), Phosphorus Pentoxide (P2O5), Poly Phosphoric Acid (PPA), and Phosphorus Pentasulfide (P2S5). These products serve as intermediates and catalysts for pharmaceuticals, agrochemicals, dyes, pigments, plastics, and lubricant additives.

Q2: What were the company’s consolidated revenue and net profit figures for FY 2025-26?

In FY 2025-26, Vital Chemtech Limited recorded consolidated revenue from operations of ₹126.44 Crores, compared to ₹133.90 Crores in FY 2024-25. Consolidated Profit Before Tax stood at ₹2.09 Crores, and Consolidated Net Profit after tax was ₹1.03 Crores (with standalone net profit reaching ₹8.95 Crores).

Q3: Who are the primary promoters and what is their equity ownership?

The company was founded and is led by Mr. Vipul Jatashanker Bhatt (Chairman & Managing Director), alongside Whole-Time Director Mr. Jay Vipul Bhatt and Non-Executive Director Mrs. Sangeeta Vipul Bhatt. As of March 31, 2026, the promoter group held 1,75,87,500 equity shares, representing 73.43% of the total equity share capital.

Q4: Where are the company’s manufacturing operations located?

The company’s manufacturing complex is located at Plot No. D-3/151 & 158 in the G.I.D.C. Dahej Industrial Estate, PCPIR region, Gujarat. The automated facility possesses an aggregate capacity of 32,000 MTPA across four dedicated manufacturing blocks operating under Zero Liquid Discharge (ZLD) environmental controls.

Q5: What are the primary growth catalysts for Vital Chemtech going forward?

Key growth drivers include commercial volume ramp-up at subsidiary Vital Synthesis Limited, capacity utilization at Vital Alkoxides Private Limited, expansion of customer approvals in advanced pharmaceutical APIs and lithium battery electrolytes, and broader market access following migration to the NSE Main Board on March 11, 2026.

Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.

Official Site: https://www.vitalgroup.co.in